205 related articles for article (PubMed ID: 26875064)
1. Is it time for treat to target strategy in osteoporosis?
Chapurlat R
Joint Bone Spine; 2016 Jul; 83(4):381-3. PubMed ID: 26875064
[No Abstract] [Full Text] [Related]
2. Management after first-line antiresorptive treatment for postmenopausal osteoporosis.
Paccou J
Joint Bone Spine; 2016 Jul; 83(4):373-5. PubMed ID: 26992951
[No Abstract] [Full Text] [Related]
3. Bisphosphonates in osteoporosis: NICE and easy?
Harvey NC; McCloskey E; Kanis JA; Compston J; Cooper C
Lancet; 2017 Nov; 390(10109):2243-2244. PubMed ID: 29165263
[No Abstract] [Full Text] [Related]
4. Current role for bone absorptiometry.
Roux C; Briot K
Joint Bone Spine; 2017 Jan; 84(1):35-37. PubMed ID: 27282091
[TBL] [Abstract][Full Text] [Related]
5. Osteoporosis and fracture risk in older people.
Coughlan T; Dockery F
Clin Med (Lond); 2014 Apr; 14(2):187-91. PubMed ID: 24715132
[No Abstract] [Full Text] [Related]
6. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
7. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
8. Real World Experience of Denosumab Treatment in the Belfast Osteoporosis Service.
Moran CP; English S; Beringer T; Lindsay JR
Ulster Med J; 2019 Sep; 88(3):150-156. PubMed ID: 31619848
[TBL] [Abstract][Full Text] [Related]
9. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture.
Simon JA; Recknor C; Moffett AH; Adachi JD; Franek E; Lewiecki EM; McClung MR; Mautalen CA; Ragi-Eis S; Nicholson GC; Muschitz C; Nuti R; Törring O; Wang A; Libanati C
Menopause; 2013 Feb; 20(2):130-7. PubMed ID: 23010883
[TBL] [Abstract][Full Text] [Related]
10. Highly different risk estimates for atypical femoral fracture with use of bisphosphonates - debate must be allowed!
Rydholm A
Acta Orthop; 2012 Aug; 83(4):319-20. PubMed ID: 22900912
[No Abstract] [Full Text] [Related]
11. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
12. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
[TBL] [Abstract][Full Text] [Related]
13. Bone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study.
Mendonça LT; Pinheiro MM; Szejnfeld VL; Castro CH
J Clin Densitom; 2017; 20(1):44-49. PubMed ID: 27616291
[TBL] [Abstract][Full Text] [Related]
14. Denosumab for postmenopausal osteoporosis?
Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
[TBL] [Abstract][Full Text] [Related]
15. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.
Adami S; Libanati C; Boonen S; Cummings SR; Ho PR; Wang A; Siris E; Lane J; ; Adachi JD; Bhandari M; de Gregorio L; Gilchrist N; Lyritis G; Möller G; Palacios S; Pavelka K; Heinrich R; Roux C; Uebelhart D
J Bone Joint Surg Am; 2012 Dec; 94(23):2113-9. PubMed ID: 23097066
[TBL] [Abstract][Full Text] [Related]
16. [Antiosteoporosis medication: useful monitoring, and how long should such treatment be continued?].
Demary W
Z Rheumatol; 2006 Sep; 65(5):370-1, 373-7. PubMed ID: 16932950
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic management of osteoporosis.
Fontenot HB; Harris AL
J Obstet Gynecol Neonatal Nurs; 2014; 43(2):236-45; quiz E20-1. PubMed ID: 24502394
[TBL] [Abstract][Full Text] [Related]
18. Use of highly potent bisphosphonates in the treatment of osteoporosis.
McClung M
Curr Osteoporos Rep; 2003 Dec; 1(3):116-22. PubMed ID: 16036074
[TBL] [Abstract][Full Text] [Related]
19. Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice.
Shevroja E; Lamy O; Kohlmeier L; Koromani F; Rivadeneira F; Hans D
J Clin Densitom; 2017; 20(3):334-345. PubMed ID: 28734710
[TBL] [Abstract][Full Text] [Related]
20. [Concordance between FRAX and Fracture Index in the prediction of the risk of osteoporosis-associated fracture in postmenopausal women].
Sastre García JF; Carbayo García JJ; Criado-Álvarez JJ; López MB
Med Clin (Barc); 2012 Mar; 138(5):225-6. PubMed ID: 22118971
[No Abstract] [Full Text] [Related]
[Next] [New Search]
